504 related articles for article (PubMed ID: 32218531)
1. Vascular toxic effects of cancer therapies.
Herrmann J
Nat Rev Cardiol; 2020 Aug; 17(8):503-522. PubMed ID: 32218531
[TBL] [Abstract][Full Text] [Related]
2. Common Vascular Toxicities of Cancer Therapies.
Herrmann J
Cardiol Clin; 2019 Nov; 37(4):365-384. PubMed ID: 31587779
[TBL] [Abstract][Full Text] [Related]
3. Adverse cardiac effects of cancer therapies: cardiotoxicity and arrhythmia.
Herrmann J
Nat Rev Cardiol; 2020 Aug; 17(8):474-502. PubMed ID: 32231332
[TBL] [Abstract][Full Text] [Related]
4. Canadian Cardiovascular Society Guidelines for Evaluation and Management of Cardiovascular Complications of Cancer Therapy.
Virani SA; Dent S; Brezden-Masley C; Clarke B; Davis MK; Jassal DS; Johnson C; Lemieux J; Paterson I; Sebag IA; Simmons C; Sulpher J; Thain K; Thavendiranathan P; Wentzell JR; Wurtele N; Côté MA; Fine NM; Haddad H; Hayley BD; Hopkins S; Joy AA; Rayson D; Stadnick E; Straatman L
Can J Cardiol; 2016 Jul; 32(7):831-41. PubMed ID: 27343741
[TBL] [Abstract][Full Text] [Related]
5. Vascular Toxicities of Cancer Therapies: The Old and the New--An Evolving Avenue.
Herrmann J; Yang EH; Iliescu CA; Cilingiroglu M; Charitakis K; Hakeem A; Toutouzas K; Leesar MA; Grines CL; Marmagkiolis K
Circulation; 2016 Mar; 133(13):1272-89. PubMed ID: 27022039
[TBL] [Abstract][Full Text] [Related]
6. Cardiovascular Complications Associated with Multiple Myeloma Therapies: Incidence, Pathophysiology, and Management.
Patel VG; Cornell RF
Curr Oncol Rep; 2019 Mar; 21(4):29. PubMed ID: 30834998
[TBL] [Abstract][Full Text] [Related]
7. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement.
Herrmann J; Lenihan D; Armenian S; Barac A; Blaes A; Cardinale D; Carver J; Dent S; Ky B; Lyon AR; López-Fernández T; Fradley MG; Ganatra S; Curigliano G; Mitchell JD; Minotti G; Lang NN; Liu JE; Neilan TG; Nohria A; O'Quinn R; Pusic I; Porter C; Reynolds KL; Ruddy KJ; Thavendiranathan P; Valent P
Eur Heart J; 2022 Jan; 43(4):280-299. PubMed ID: 34904661
[TBL] [Abstract][Full Text] [Related]
8. Cardiovascular toxic effects of targeted cancer therapy.
Tajiri K; Aonuma K; Sekine I
Jpn J Clin Oncol; 2017 Sep; 47(9):779-785. PubMed ID: 28531278
[TBL] [Abstract][Full Text] [Related]
9. Cardiotoxicity of Biological Therapies in Cancer Patients: An In-depth Review.
Madanat L; Gupta R; Weber P; Kumar N; Chandra R; Ahaneku H; Bansal Y; Anderson J; Bilolikar A; Jaiyesimi I
Curr Cardiol Rev; 2023; 19(3):e310522205428. PubMed ID: 35642110
[TBL] [Abstract][Full Text] [Related]
10. Common Cardiovascular Complications of Cancer Therapy: Epidemiology, Risk Prediction, and Prevention.
Narayan V; Ky B
Annu Rev Med; 2018 Jan; 69():97-111. PubMed ID: 29414258
[TBL] [Abstract][Full Text] [Related]
11. Vascular Toxicity in Patients with Cancer: Is There a Recipe to Clarify Treatment?
Alvarez-Cardona J; Mitchell J; Lenihan D
Methodist Debakey Cardiovasc J; 2019; 15(4):289-299. PubMed ID: 31988690
[TBL] [Abstract][Full Text] [Related]
12. Oxidative stress in anticancer therapies-related cardiac dysfunction.
Attanasio U; Pirozzi F; Poto R; Cuomo A; Carannante A; Russo M; Ghigo A; Hirsch E; Tocchetti CG; Varricchi G; Mercurio V
Free Radic Biol Med; 2021 Jun; 169():410-415. PubMed ID: 33930514
[TBL] [Abstract][Full Text] [Related]
13. Cardio-oncology - strategies for management of cancer-therapy related cardiovascular disease.
Totzeck M; Schuler M; Stuschke M; Heusch G; Rassaf T
Int J Cardiol; 2019 Apr; 280():163-175. PubMed ID: 30661849
[TBL] [Abstract][Full Text] [Related]
14. The cancer patient and cardiology.
Zamorano JL; Gottfridsson C; Asteggiano R; Atar D; Badimon L; Bax JJ; Cardinale D; Cardone A; Feijen EAM; Ferdinandy P; López-Fernández T; Gale CP; Maduro JH; Moslehi J; Omland T; Plana Gomez JC; Scott J; Suter TM; Minotti G
Eur J Heart Fail; 2020 Dec; 22(12):2290-2309. PubMed ID: 32809231
[TBL] [Abstract][Full Text] [Related]
15. Myocardial Dysfunction in Patients with Cancer.
Koutroumpakis E; Agrawal N; Palaskas NL; Abe JI; Iliescu C; Yusuf SW; Deswal A
Heart Fail Clin; 2022 Jul; 18(3):361-374. PubMed ID: 35718412
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular toxic effects of antitumor agents: Pathogenetic mechanisms.
Pantazi D; Tselepis AD
Thromb Res; 2022 May; 213 Suppl 1():S95-S102. PubMed ID: 36210569
[TBL] [Abstract][Full Text] [Related]
17. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: The Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC).
Zamorano JL; Lancellotti P; Rodriguez Muñoz D; Aboyans V; Asteggiano R; Galderisi M; Habib G; Lenihan DJ; Lip GYH; Lyon AR; Lopez Fernandez T; Mohty D; Piepoli MF; Tamargo J; Torbicki A; Suter TM;
Eur Heart J; 2016 Sep; 37(36):2768-2801. PubMed ID: 27567406
[No Abstract] [Full Text] [Related]
18. Cancer Therapies and Vascular Toxicities.
Meilhac A; Cautela J; Thuny F
Curr Treat Options Oncol; 2022 Mar; 23(3):333-347. PubMed ID: 35244888
[TBL] [Abstract][Full Text] [Related]
19. Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients.
van Dorst DCH; Dobbin SJH; Neves KB; Herrmann J; Herrmann SM; Versmissen J; Mathijssen RHJ; Danser AHJ; Lang NN
Circ Res; 2021 Apr; 128(7):1040-1061. PubMed ID: 33793337
[TBL] [Abstract][Full Text] [Related]
20. Clinical roles of vascular function assessment in cancer care.
Sawami K; Tanaka A; Node K
Support Care Cancer; 2022 Feb; 30(2):985-987. PubMed ID: 34378082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
